ARC welcomed Jan Griffin, MD, amyloidosis cardiologist at the Medical University of South Carolina. Dr. Griffin discussed how ATTR affects the heart and explored advances in treatments for ATTR-CM.
She explained the medications currently available, how they work, how doctors know if they’re helping, and what new treatments are coming in the future.
The webinar concluded with a Q&A session.
Original Presentation Date:
June 10, 2025.
0:00 — Welcome
3:39 — Introduction
5:52 — ATTR Cardiac Amyloidosis Overview
TTR Stabilizers
10:31 — Vyndamax® / Vyndaqel® (tafamidis)
14:17 — Attruby™ (acoramidis)
TTR Silencers
18:30 — Amvuttra® (vutrisiran)
21:35 — Eplontersen
Gene Editing
24:12 — Nex-z (NTLA-2001)
28:31 — MAGNITUDE Study
Depleting TTR
30:35 — ALXN2220 (NI006)
34:39 — Coramitug (NNC6019/PRX004)
Prevention
36:23 — ACT-EARLY Trial
38:05 — Summary of ATTR Cardiac Therapies
39:12 — Combination Therapy
43:58 — How to Choose Initial Therapy
47:16 — Adjunctive Therapies for Heart Failure
51:40 — ARC Summary of Approved Treatments for ATTR-CM
52:32 — Q&A Session
52:48 — If I’m on one treatment, how should I go about considering other treatments?
55:17 — How often is Amvuttra® (vutrisiran) administered?
55:35 — How does Vitamin A function with reduced TTR?
56:55 — Where and how can I access gene editing treatments?
58:30 — When might some of the treatments currently under investigation become available?
1:00:26 — How frequently should I have my biomarkers and medical imaging monitored?
1:02:13 — What are the side effects/risks of taking tafamidis?
1:03:12 — Conclusion
Contact ARC:
Call +1 (617) 467-5170
Email ARC at support@arci.org
